OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
10
Results
Show all
Save search
Copy query
Show results for
Unknown
(10)
Publication Date
Release Date
2023
(2)
2015
(2)
2022
(1)
2020
(1)
2019
(1)
2017
(1)
2016
(1)
2014
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus.
Not available
S-EPMC4210070
|
biostudies-literature
Cite
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
Not available
S-EPMC4342773
|
biostudies-literature
Cite
Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Not available
S-EPMC6624389
|
biostudies-literature
Cite
Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.
Not available
S-EPMC7136367
|
biostudies-literature
Cite
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study.
Not available
S-EPMC5024052
|
biostudies-literature
Cite
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Not available
S-EPMC4931205
|
biostudies-literature
Cite
Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials.
Not available
S-EPMC6224932
|
biostudies-literature
Cite
Bayesian-based decipherment of in-depth information in bacterial chemical sensing beyond pleasant/unpleasant responses.
Not available
S-EPMC8863824
|
biostudies-literature
Cite
Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti-seizure medication.
Not available
S-EPMC10472371
|
biostudies-literature
Cite
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
Not available
S-EPMC10444729
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets